Tildrakizumab positioning in plaque psoriasis treatment – 2018 Pipeline Review

Where will tildrakizumab be positioned in the psoriasis marketplace once approved by the FDA?

Plaque psoriasis (psoriasis vulgaris) (ICD-10 L40.0), which is commonly referred to simply as psoriasis, is the most common form of the skin disease with a prevalence of 2-3% worldwide.  GlobalData estimates that the biologics total drug sales for psoriasis in 2012 was valued at $5.35 billion across the nine markets.  How will tildrakizumab, currently under review by the FDA with an anticipated approval in March of 2018, compare with other drugs with a similar mechanism of action?

For our complete review of tildrakizumab :

GET THE FULL REVIEW AT THE RESOURCE LIBRARY

Other Marketed and Approved Injectable Treatment Alternatives:

Generic Name Marketed/

Approved

Brand Name Classification ROA FDA population Maintenance Frequency Company Name
adalimumab Marketed Humira® tumor necrosis factor (TNF) blocker SC Adult Every Other Week AbbVie Inc
adalimumab-adbm Approved CyltezoTM tumor necrosis factor (TNF) blocker SC Adult Every Other Week Boehringer Ingelheim Pharmaceuticals Inc
adalimumab-atto Approved AmjevitaTM tumor necrosis factor (TNF) blocker SC Adult Every Other Week Amgen Inc
etanercept Marketed Enbrel® tumor necrosis factor (TNF) blocker SC 4 years and older Every Week Amgen Inc
etanercept-szzs Approved ErelziTM tumor necrosis factor (TNF) blocker SC Adults Every Week Sandoz Inc
infliximab Marketed Remicade® tumor necrosis factor (TNF) blocker IV Adult Every 8 Weeks Janssen Biotech Inc
infliximab-abda Marketed RenflexisTM tumor necrosis factor (TNF) blocker IV Adult Every 8 Weeks Merck & Co Inc
infliximab-dyyb Marketed Inflectra® tumor necrosis factor (TNF) blocker IV Adult Every 8 Weeks Pfizer Inc
infliximab-qbtx Approved – No plans for marketing in US IxifiTM tumor necrosis factor (TNF) blocker IV Adult Every 8 Weeks Pfizer Inc
guselkumab Marketed Tremfya® interleukin-23 blocker SC Adult Every 8 Weeks Janssen Biotech Inc
brodalumab Marketed SiliqTM interleukin-17A antagonist SC Adult Every 2 weeks Valeant Pharmaceuticals International
ixekizumab Marketed Taltz® interleukin-17A antagonist SC Adult Every 4 Weeks Eli Lilly and Co
secukinumab Marketed Cosentyx® interleukin-17A antagonist SC Adults Every 4 Weeks Novartis Pharmaceuticals Corp
ustekinumab Marketed Stelara® interleukin-12 and -23 antagonist SC 12 years and older Every 12 Weeks Janssen Biotech Inc

Please note: The following drugs were not included due to the lack of a FDA approved indication, moderate-to-severe plaque psoriasis: certolizumab pegol (Cimzia), golimumab (Simponi & Simponi Aria) and abatacept (Orencia).  IV formulations listed above are generally reserved for more chronic, severe psoriasis.

References:

Global Data Pharma Intelligence Center https://pharma.globaldata.com  Accessed February 28, 2018

RJ Health Systems RC Reimbursement Codes https://www.reimbursementcodes.com  Accessed February 21, 2018

NIH U.S. National Library of Medicine ClinicalTrails.gov https://clinicaltrials.gov/ct2/home  Accessed February 20. 2018

U.S. Department of Health and Human Services. U.S. Food and Drug Administration Drugs https://www.fda.gov/Drugs/default.htm  Accessed February 20. 2018

 

 


If this caught your interest, for a similar review of the rituximab biosimilar pipeline, please go to the summary blog for a link to log into and register to receive the full publication.